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Abstract
Lung transplantation has become an increasingly important modality for the 
treatment of severe lung disease. From its inception, the procedure has been refined 
so that it now represents the standard of care for end stage respiratory failure. The 
widespread adoption of this treatment option, however, has brought into sharp 
relief the current organ donor shortage. In tandem with the explosion in lung 
transplant procedures, a number of support modalities have seen an expanded role. 
Perhaps one of the most versatile tools in the armamentarium of the pulmonary 
transplant surgeon is extracorporeal membrane oxygenation (ECMO). This power-
ful tool is being increasingly implemented in all stages of lung transplantation—
from supporting the failing native organ as a bridging tool to transplantation, to 
stabilizing the patient intra-operatively during the transplant procedure, to rescu-
ing the patient with severe primary graft dysfunction immediately post-transplant. 
A number of advanced techniques for the application of ECMO in order to optimize 
the pulmonary transplant procedure are gaining traction—and with ECMO’s 
expanded role in lung transplantation, so also has come a new set of technical and 
ethical challenges that must also be overcome.
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1. Introduction
Lung transplantation has become an increasingly important modality for the 
treatment of severe lung disease. From its inception in 1985, the procedure has been 
refined so that it now represents the standard of care for end stage respiratory failure. 
As the efficacy of this treatment has been proven, we have seen the frequency of lung 
transplantation undergo an exponential rise. In 1993, for example, the International 
Society for Heart and Lung Transplantation (ISHLT) reports that a total of 1055 
lung transplant procedures was performed. A decade later in 2003, that number had 
nearly doubled to 1934 and in 2013, the number of lung transplant procedures per 
year rose to 3892 [1]. In the same vein, a study in 2018 analyzing national trends of 
extracorporeal membrane oxygenation use in the National Inpatient Sample identi-
fied an over 360% increase in admissions for ECMO support from 2008 to 2014, 
among which mortality decreased among total admissions from over 60% down to 
43% despite a trend toward an increased risk profile [2]. The widespread adoption of 
this treatment option, however, has brought into sharp relief the current organ donor 
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shortage; there is currently a yearly potential lung transplant recipient mortality of 
up to 16% while awaiting organs to become available [3].
In tandem with the explosion in lung transplant procedures, a number of 
support modalities have seen an expanded role. Perhaps one of the most versatile 
tools in the armamentarium of the pulmonary transplant surgeon is extracorporeal 
membrane oxygenation (ECMO). This powerful tool is being increasingly imple-
mented in all stages of lung transplantation—from supporting the failing native 
organ as a bridging tool to transplantation, to stabilizing the patient intraopera-
tively during the transplant procedure, to rescuing the patient with severe primary 
graft dysfunction immediately post-transplant. A number of advanced techniques 
for the application of ECMO in order to optimize the pulmonary transplant proce-
dure are gaining traction—and with ECMO’s expanded role in lung transplantation, 
so to have come a new set of technical and ethical challenges that must also be 
overcome.
The goal of this chapter is to discuss some of the recent advances in the applica-
tion of ECMO in the setting of lung transplantation. We discuss the application of 
ECMO in the preoperative, perioperative, and postoperative period, and focus in 
particular on advances such as the use of awake ECMO and various cannulation 
strategies. We also briefly discuss some of the ethical issues surrounding ECMO for 
lung transplantation, including cost, quality of life, and the application of ECMO to 
marginal recipients.
2. VV- and VA-ECMO in lung transplantation
In the setting of lung transplantation, ECMO may be utilized in either a veno-
venous (VV) or a veno-arterial (VA) configuration. The VV-ECMO modality is 
used strictly for respiratory support; this review will explore the current frontiers 
of usage in in the setting of either pre-operative bridge to transplant, as well as for 
bridging to graft recovery the subset of patients who develop severe post-transplant 
primary graft dysfunction (PGD). Alternatively, VA-ECMO may be utilized in 
the subset of patients with either pulmonary arterial hypertension requiring both 
cardiac and pulmonary support in the preoperative period, recently transplanted 
patients exhibiting hemodynamic instability, or in the intra-operative period for 
cardiopulmonary support [4].
Cannulation strategies for VA- and VV-ECMO are listed here. VV-ECMO is typi-
cally achieved via outflow and inflow cannulas in the femoral and internal jugular 
veins, with the tip of the drainage cannula placed to the level of the inferior vena cava-
right atria junction and the tip of the return cannula at the right atrium. Alternatively, 
VV-ECMO may be achieved via a femoral-femoral cannulation strategy, with the tip 
of the drainage cannula in inferior vena cava and the tip of the outflow cannula is in 
the right atrium. Alternatively, a one-site cannulation strategy makes use of a dual 
lumen Avalon cannula (Avalon Elite, Maquet, Rastatt, Germany) percutaneously 
placed in the either internal jugular vein or in the subclavian vein [5].
VA-ECMO cannulation may be achieved using either a peripheral or central 
cannulation strategy. In a peripheral cannulation strategy, the femoral vein and 
artery are cannulated in a percutaneous fashion, with the tip of the arterial cannula 
placed in the common iliac artery. Alternatively, the arterial inflow cannula can be 
placed into the right subclavian artery. Because these peripheral strategies may in 
some cases only transmit arterial blood flow as far as the aortic arch (where blood 
oxygenated from the patient’s native lungs and transmitted by the patient’s heart) 
this may have the effect of poorly perfusing the heart and lungs (known as the 
Harlequin Syndrome). In this case, central cannulation of VA-ECMO is an option, 
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with the venous cannula placed directly in the right atrium and the arterial cannula 
placed in the ascending aorta through a median sternotomy incision [4].
A number of hybrid options also exist for selected scenarios; these include 
Veno-veno-arterial ECMO (VVA-ECMO) where an additional venous cannula is 
inserted to offload the left ventricle, typically into the right internal jugular vein. 
This may also describe the conversion of veno-venous (VV) ECMO to additionally 
supply cardiac support by the insertion of an arterial cannula. Other triple-catheter 
strategies include the insertion of a distal perfusion cannula to the cannulated 
lower extremity in peripheral VA-ECMO in order to decrease limb ischemia. This 
armamentarium provides the surgeon with a number of different techniques for 
providing either isolated pulmonary or cardiopulmonary support in the transplant 
patient.
3. ECMO in the preoperative period
3.1 ECMO as a bridge to lung transplantation
The first successful use of ECMO in the preoperative period prior to lung 
transplant may be traced back to 1975, when ECMO was described as being initiated 
to correct a profound hypercapnia in a 19-year-old boy prior to transplantation. 
While the patient was successfully removed from the oxygenator and weaned from 
mechanical ventilation, he ultimately died on the eighteenth postoperative day due 
to a bronchial dehiscence [6]. For the next 20 years, this modality was occasionally 
described in the literature in case studies; however, it was associated with dismal 
outcomes and as a result did not gain widespread use.
In the past decade, however, there have been a number of advances in both the 
technology surrounding ECMO, and the management of the patient on ECMO, such 
that institutions are increasingly turning back to preoperative ECMO as an accept-
able or even preferred modality for bridging patients with end stage respiratory dis-
ease to lung transplantation. This shift in management was preempted by a number 
of forces. First, the institution of the lung allocation score in 2005 allowed for more 
efficacious allocation of donor organs to those patients most emergently in need 
of a transplants rather than just the length of time on the waiting list. This meant 
that patients receiving continuous mechanical ventilation were listed with scores. 
ECMO was found to serve as a useful tool to stabilize ventilator-dependent patients 
approaching transplantation. Additionally, multicenter trials in the non-transplant 
population began to demonstrate the effectiveness of ECMO in ameliorating severe 
adult respiratory distress syndrome [7]. With the significant improvement in 
ECMO technologies, an increasing number retrospective and prospective studies 
have been conducted that show promising outcomes related to the use of ECMO as a 
bridging strategy [5, 8–17].
Some of those studies are reported here. Much of the initial research consisted 
of single-center retrospective studies. One of the first studies to demonstrate the 
efficacy of this therapy reported 17 bridged patients with a 78% 1-year survival 
after transplant, among whom allograft function did not differ between patients 
who did and did not receive ECMO bridging support [8]. A 2012 institutional study 
of 11 patients demonstrated shorter durations of mechanical support, and shorter 
post-transplant ICU and hospital stay in patients bridged with ECMO; a 1-year 
survival rate of over 85% after ECMO compared to 50% in patients with traditional 
mechanical ventilation was highlighted [15]. In 2013, a retrospective review of the 
medical records of 39 French patients bridged to lung transplantation on ECMO 
highlighted successful bridging to transplant in over 80% of the population, 
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perioperative survival of 75%, and successful discharge from the hospital in 50%. 
While 2-year survival was largely a function of the underlying disease state, 
outcomes were largely similar between the ECMO and non-ECMO use groups, 
supporting the use of ECMO as a bridge to lung in order to preserve a medium-term 
survival benefit in the critically ill [14].
A large single-institution study retrospectively reviewed 715 consecutive lung 
transplants performed between the start of LAS implementation in May of 2005 
until September 2011, of which 3.4% were performed on patients with attempted 
pre transplant ECMO. While patients in the pre-transplant ECMO group had 
significantly higher lung allocation scores, and median hospital stay was nearly 
double that for the ECMO group compared to the control group there was no 
difference in survival, with an overall 2-year survival approaching 75% in both 
cohorts [16]. A 2017 retrospective single-institution study looking particularly 
at cardiac outcomes in the population bridged to lung transplantation on ECMO 
identified a successful bridging rate of 60%, with a 1-year survival of over 90%. 
This study in particular noted right ventricular systolic dysfunction and worsening 
volume overload to be associated with unsuccessful bridging, but otherwise identi-
fied adequate outcomes [18].
In order to overcome some of the weaknesses of small retrospective cohorts, the 
question of ECMO’s efficacy as a bridging strategy to transplant has been addition-
ally queried of large national databases. A 2015 study of the United Network for 
Organ Sharing (UNOS) database highlighted 119 patients who were bridged to 
transplantation using extracorporeal membrane oxygenation compared to 12,339 
patients who were not. The study period was divided into four 3-year intervals, and 
this demonstrated both an increasing number of patients bridged per year with 
ECMO and progressively increasing survival with each period, as did the number 
of patients bridged using extracorporeal membrane oxygenation. This highlights 
that short-term survival with the use of extracorporeal membrane oxygenation as a 
bridge to lung transplantation continues to significantly improve as it is more widely 
adopted [19].
The use of bridge-to-transplant with ECMO has also been trialed in small 
cohorts consisting of patient subsets at increased risk due to the presence of comor-
bidities. For example, this therapy has been demonstrated as effective in patients 
with cystic fibrosis; the authors of a 2012 case series of this population demonstrate 
good perioperative outcomes and describe the early initiation of ECMO soon after 
development of acute respiratory failure requiring mechanical ventilation as an 
important part of the treatment algorithm for these patients due to their high risk of 
ventilator-acquired complications [20]. Furthermore, in the subset of patients with 
advanced interstitial lung disease and secondary pulmonary hypertension, medical 
management remains complex and mechanical ventilator support are associated 
with poor outcomes. Small retrospective reviews, however, suggest that this subset 
had at least a comparable survival when requiring an extracorporeal membrane 
oxygenation bridge to that of other high acuity patients placed on extracorporeal 
membrane oxygenation as a bridge to lung transplantation [21]. Taken in sum, these 
studies suggest that extracorporeal membrane oxygenation is a feasible tool for use 
as a bridge to lung transplantation.
3.2 Awake and ambulatory ECMO
One benefit of ECMO compared to normal mechanical ventilation is that 
extracorporeal membrane oxygenation allows for adequate oxygenation to occur in 
patients who are awake, spontaneously breathing, and liberated from the ventilator. 
This could potentially represent a novel bridging strategy in that the complications 
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associated with prolonged mechanical ventilation, such as ventilator-acquired 
pneumonia, are avoided. For example, a 2012 retrospective, single-center analysis 
of consecutive potential lung transplant patients receiving awake ECMO sup-
port compared with a historical control group receiving conventional mechanical 
ventilation demonstrated a 6-month survival after lung transplantation at 80% in 
the awake ECMO group versus 50% in the mechanical ventilation group. They also 
had shorter postoperative recovery periods [10].
In addition to avoiding mechanical ventilation complications, freedom from the 
vent also allows for novel rehabilitation efforts, such as ambulation and physical 
therapy while on ECMO, which could potentially help to stave off decondition-
ing while awaiting transplantation in the unit. Subjects on awake ECMO usually 
received a combination of passive and active physiotherapy; emerging research in 
the field affords preliminary evidence supporting the safety of early mobilization 
and ambulation in patients on awake ECMO support [22]. For example, a retrospec-
tive observational study in which ECMO patients were managed with early aggres-
sive physical therapy, ambulation, and spontaneous breathing led to 30-day, 1-year, 
and 3-year survival outcomes after transplant of 92, 85, and 80%, respectively [11]. 
A second retrospective study compared five pre-transplant ECMO patients receiving 
active rehabilitation and ambulation to patients who were bridged with ECMO but 
did not receive pre-transplant rehabilitation. A third study of 72 patients receiving 
ECMO as a bridge to lung transplantation of which daily participation in physical 
therapy was achieved in 50 patients demonstrated favorable survival in patients 
receiving ECMO as a bridge to lung transplantation, particularly good outcomes 
in patients receiving physical therapy and maintaining avoidance of mechanical 
ventilation, and high rates of successful ambulation and therapy in the overall 
ECMO group [9]. Pre-transplant physical therapy was associated with shorter mean 
post-transplant mechanical ventilation, intensive care stay, and overall hospital days 
[23]. In general, preservation of pre-transplant ambulatory status has been found 
to improve outcomes in patients bridged to lung transplantation with ECMO [24]. 
These are encouraging findings support the concept that ambulatory ECMO allows 
for preservation of vitality while critically ill candidates await donor organs, which 
may improve outcomes.
Efforts to ambulate patients on ECMO bridging to lung transplant have been 
aided by the implementation of single-site, dual-lumen cannulation via an Avalon 
catheter. In conventional VV-ECMO, the outflow and inflow cannulas are placed 
percutaneously using the Seldinger technique, most commonly in the femoral 
and internal jugular veins. Alternatively, a one-site cannulation strategy makes 
use of a dual lumen Avalon cannula (Avalon Elite, Maquet, Rastatt, Germany) 
percutaneously placed in the either internal jugular vein or in the subclavian vein, 
under direct imaging such as fluoroscopy or transesophageal echocardiogram. 
This approach avoids use of the femoral site, which aids in mobilization and may 
limit the risk of recirculation and groin infectious complications [5]. Downsides 
include the need for precise placement and orientation of the catheter, requiring 
fluoroscopic guidance; femoral-femoral or femoral-jugular cannulation is much 
more expeditious, and suited to emergency situations. The Avalon catheter is 
also significantly more expensive than more conventional cannulation strategies 
[4]. Ultimately, however, the complication rate of this approach is comparable to 
traditional two-site ECMO in most studies [25], and many centers are now routinely 
using single-site ECMO as a first-line cannulation strategy.
Awake ECMO has been shown to be particularly effective for those patients at 
elevated risk of deconditioning. For example, the subset of patients requiring lung 
re-transplantation is a particularly challenging transplantation cohort because 
of the critical illness often associated with graft failure, as well as the higher 
Advances in Extracorporeal Membrane Oxygenation - Volume 3
6
likelihood of deconditioning after transplant failure. In a 2014 study looking 
specifically at this group, re-transplant patients bridged on awake, ambulatory 
ECMO support demonstrated a mortality of 0% compared to 39% in the group 
requiring mechanical ventilation The study concludes that awake ECMO bridging 
for re-transplantation provides comparable results to elective re-transplantation 
[26]. Larger retrospective studies have also made use of clinical databases such 
as the United Network for Organ Sharing database. In 2016, a study of all adult 
patients undergoing isolated lung transplantation in the last decade were identi-
fied based on their need for preoperative support: no support versus ECMO, 
invasive mechanical ventilation, or both, while 1-year survival was decreased in 
all patients requiring any type of support, mid-term survival was comparable 
between patients on ECMO alone and those not requiring support, but signifi-
cantly worse with patients requiring mechanical ventilation with or without 
ECMO. This highlights the fact that those patients supported via ECMO with 
spontaneous breathing demonstrate improved survival compared with mechani-
cal ventilation [27].
3.3 CO2 removal in the bridge-to-transplant population
In patients awaiting lung transplantation, adequate gas exchange may not be suf-
ficiently achieved by ventilation alone if acute respiratory decompensation arises. 
This may result in a life-threatening hypercapnia. ECMO may serve an additional 
purpose in patients bridging to lung transplantation as an adjunct for CO2 removal 
(ECCO2-R). For some patients, increased CO2 clearance may spare them the need 
for mechanical ventilation [28]. A 2016 study of 20 patients (15 invasively venti-
lated and five noninvasively ventilated patients) demonstrated effective correction 
of hypercapnia and acidosis within the first 12 hours of therapy. Nineteen patients 
were successfully transplanted, and hospital and 1-year survival was 75 and 72%, 
respectively. This highlights ECCO2-R as a feasible rescue therapy that can be associ-
ated with high transplantation and survival rates [29].
3.4 Prolonged bridging with ECMO
Outcomes in the unique subset of patient requiring the prolonged use of ECMO 
prior to lung transplantation have in recent years become the subject of study. 
For example, in a 2016 review of 974 patients who required prolonged (>14 days) 
ECMO in the Extracorporeal Life Support Organization international multi-
institutional registry, 46% of these patients did not sustain native lung recovery; 
among these, 40 patients (4.1%) underwent lung transplant with a 50% post-
operative in-hospital mortality [30]. While 14 days appears to be the consensus 
after which ECMO is considered to be prolonged, the upper bounds for the length 
of time for which ECMO can be continued as a bridging method continue to be 
tested. For example, a recent case report describes a patient remaining on ECMO 
for as long as 403 days while waiting for a lung transplant. This required changing 
the membrane oxygenator 23 times and the cannula 10 times; This therapy was 
ultimately terminated due to a loss of access for cannula insertion. The authors 
conclude that it is at least technically feasible to maintain patients awaiting lung 
transplantation on ECMO for extended periods of time, albeit maintaining for 
than 1-year may be difficult [31]. While case reports have described successful 
transplantation after many months on ECMO support, ultimately the outcomes 
remain dismal in this cohort; for example, as late as 2016 there were no recorded 
cases of pediatric long-term post-transplant survival after more than 52 days on 
ECMO support [32].
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3.5 Selected issues in bridge-to-transplant
3.5.1 Cost-effectiveness
With the increasing utilization of ECMO in the lung transplant population, the 
question of utility is growing in importance. Recent studies have examined the cost 
associated with the use of extracorporeal membrane oxygenation in the setting 
of lung transplantation. A 2017 study using the Nationwide Inpatient Sample 
evaluated hospital charges of patients undergoing lung transplant who required 
ECMO during their hospital course; represented 4.2% of the patients undergoing 
lung transplantation overall. Median charges for lung transplant recipients who 
required ECMO were $780,391.50 versus $324,279.80 for non-ECMO recipients; the 
characteristics particularly associated with exorbitant hospital costs included black 
recipient race, pulmonary hypertension, and Medicare enrollees [33]. Studies have 
shown a disproportionately high amount of extracorporeal membrane oxygenation 
use in the Northeast compared to other parts of the country; this is highlighted as a 
regional disparity [2].
The economic impact of ambulatory versus either non-ambulatory ECMO 
strategies or mechanical ventilation as a bridge to lung transplantation is also of 
interest. In a retrospective 2016 study at a single center, subjects who were reha-
bilitated while supported with ECMO before lung transplantation were compared 
with those who were not rehabilitated during ECMO. When hospital cost data for 
the month before transplantation through 12 months after initial post-transplant 
hospital discharge were compared, subjects supported with ambulatory ECMO had 
a 22% (greater than $60,000) reduction in total hospital cost, 73% (greater than 
$100,000) reduction in post-transplant ICU costs, and 11% (greater than $30,000) 
reduction in total costs compared with non-ambulatory ECMO subjects [34].
3.5.2 Quality of life
With the increasing use of extracorporeal membrane oxygenation as a bridge 
to lung transplantation, the impact of preoperative ECMO on quality of life and 
depressive symptoms has been additionally targeted as an area of study. This 
question stems from the possibility that, due to complications after ECMO coupled 
with critical illness in the period up to transplantation may have adverse effects of 
quality of life in patients after transplantation. This does not appear to be the case; 
a 2018 single-institution prospective cohort study found that lung transplantation 
provides substantial quality of life improvements following lung transplantation, 
and these were generally similar among patients on pre-operative ECMO compared 
to those patients brought in for transplantation from the outpatient setting [35]. 
A second study in 2017 examining quality of life in ECMO-bridge lung transplant 
recipients demonstrated that outcomes after successful transplantation after ECMO 
are comparable with the general population undergoing lung transplantation in 
terms of quality of life, lung function, performance tests, and mortality [36].
3.5.3 Quality of the data
The increasing need for multi-institutional analysis of ECMO usage has had the 
effect of highlighting the dramatic differences in the implementation of ECMO at 
various programs. A survey of all US lung transplant centers in showed that two-
thirds of responding centers used of ECMO as a bridge to transplant. Among these, 
a patient age greater than 65 was a cutoff in nearly half of centers, but otherwise 
many centers had no official age cutoff. Additionally, there was little consensus on 
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the upper bounds for an acceptable duration of pre-transplant ECMO therapy, and 
this varied from as little as 10 days to a policy in which ECMO support duration was 
not bounded. Overall, the institutional criteria for ECMO initiation, age limits, and 
duration of support are widely disparate across centers [37].
A systematic review in 2014 highlighted the inconsistencies in design between 
these studies; while 82 potential studies of ECMO bridging were identified at the 
time, the vast majorities were excluded and the broad heterogeneity among the 
studies precluded any wider meta-analysis. In this analysis, the preoperative mortal-
ity rate of patients on ECMO ranged from 10–50%. It was ultimately concluded that 
ECMO support as a bridge could potentially provide reasonable perioperative and 
1-year survival outcomes, but no broader statement could be made owing to a gen-
eral paucity of high-quality data and significant heterogeneity among studies [38].
While these largely retrospective studies are compelling, it is acknowledged 
that retrospective studies are not the ideal candidates for definitively proving the 
efficacy of ECMO compared to mechanical ventilation, which has in tandem with 
ECMO evolved in the past decade to include more advanced strategies of protective 
lung ventilation. While the challenges of randomizing patients to different thera-
pies in end-stage respiratory failure are apparent, at this point significant equipoise 
now exists to justify the randomized comparison of ECMO with standard ventilator 
therapy as a bridging strategy [39].
4. ECMO in the peri- and postoperative period
4.1 ECMO versus cardiopulmonary bypass
While partial or full cardiopulmonary support was initially a necessary aspect 
of lung transplantation, this has become less of a requirement with improvements 
in ventilation and operative technique. However, for those cases where cardio-
pulmonary support remains a necessity (such as failure of single lung ventilation, 
or right heart failure), VA ECMO is playing an increasing role as an alternative to 
traditional cardiopulmonary bypass. Cardiopulmonary bypass is at least theoreti-
cally responsible for the development of pulmonary injury and has been implicated 
in adult respiratory distress syndrome [40]. Pulmonary injury during cardiopul-
monary bypass has been the subject of a significant amount of research over the 
past 30 years. At this time, it is theorized that lung damage occurs as the result of an 
inflammatory cascade triggered by a combination of surgical trauma, the interface 
of blood products with the extracorporeal circuit, and lung reperfusion injury; this 
triggers the generation of oxygen free radicals that are in turn sequestered within 
the lung and lead to pulmonary injury [41, 42].
Other issues related to cardiopulmonary bypass include a need for high-dose 
heparinization, which can lead to intra- and postoperative bleeding complications, 
and high blood turnover with a high volume of blood necessary to load the circuit. 
Cardiopulmonary bypass also requires central cannulation that can preclude other 
interventions in the operative field such as coronary artery bypass grafting. These 
issues have led providers to seek alternate supportive options. On its face, ECMO 
has a number of perceived benefits over cardiopulmonary bypass. With this in 
mind, there have been a number of studies comparing the efficacy of ECMO to 
cardiopulmonary bypass in the lung transplant setting [43–50].
The first studies of VA ECMO as a replacement therapy were not initially 
associated with good outcomes. For example, in 2007 a single institute retrospective 
study, ECMO was found to have a trend toward increased 90-day mortality rate, 
a higher incidence of severe graft ischemia/reperfusion injury, and a significantly 
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reduced 1-year survival compared to cardiopulmonary bypass [45]. However, with 
increasing experience in using ECMO, results have been more promising. A 2012 
retrospective study of outcomes of patients treated using ECMO versus cardio-
pulmonary bypass demonstrated a higher transfusion requirement in the cardio-
pulmonary bypass group, as well as a significantly higher incidence of in-hospital 
mortality, the need for hemodialysis, and new postoperative ECMO support. In this 
study transplantation with cardiopulmonary bypass was identified as an indepen-
dent risk factor for in-hospital mortality [51].
In a 2014 study comparing differences in 47 lung transplant patient outcomes 
with intraoperative ECMO versus cardiopulmonary bypass, the ECMO group was 
required fewer transfusions and had less bleeding, fewer reoperations, and less 
primary graft dysfunction with no 30-day or 1-year survival differences [44]. 
Similarly, in a 2014 comparison of 271 consecutive patients who underwent lung 
transplant using either cardiopulmonary bypass or ECMO, there were differences 
in 30-day or 6-month mortality, and less postoperative complications among the 
ECMO group [43]. A number of more recent studies similarly comparing VA ECMO 
to cardiopulmonary bypass have confirmed the finding of a lower perioperative 
blood product transfusion requirement and lower 90-day mortality among the 
extracorporeal membrane oxygenation cohorts [48, 49, 52, 53].
Recently, a meta-analysis of the existing evidence to support ECMO versus car-
diopulmonary bypass showed beneficial trends of ECMO regarding blood transfu-
sions, duration of ventilator support and intensive care unit length of stay, 3-month 
and 1-year mortality; these findings, however, were not statistically significant. At 
this time, while it appears that ECMO is at least non-inferior to cardiopulmonary 
bypass in the setting of lung transplantation, the superiority of ECMO remains to 
be determined and will likely require larger multi-center randomized trials [47].
Outcomes compared between patients requiring intraoperative ECMO versus 
those not requiring any support are less conclusive; in a 2018 study of 53 patients, 
while patients who underwent ECMO received more intraoperative transfusions, 
outside of the immediate postoperative period there were no differences in in-hos-
pital and 6-month complications with similar survival between the two groups [50]. 
In contrast, however, a 2017 single institution study demonstrated 5-year survival 
to be 52.8% in intraoperative ECMO recipients versus 70.5% in those not requiring 
ECMO, with multivariate analysis identifying intraoperative ECMO support as 
significant risk factors for overall survival [46].
4.2 Postoperative ECMO for primary graft dysfunction
Early primary graft dysfunction, defined as lung injury causing decreased oxy-
genation during the first 3 days after lung transplant, is a devastating albeit fairly 
uncommon occurrence. ECMO is a useful adjunct for supporting the patient with 
primary graft dysfunction, either to recovery or as a bridge to redo transplantation.
One-year survival is compromised in patients with severe primary graft 
dysfunction compared to those without; in addition to the underlying causal 
factors contributing to dysfunction in the first place, this is often worsened by the 
high airway pressures and inspired oxygen concentration necessary to adequately 
oxygenate the patient via mechanical ventilation. ECMO may be desirable for its 
ability to avoid these risk factors. In a single-institution study of patients with 
primary graft dysfunction, successful weaning from ECMO was achieved in 96% 
of patients, with substantially improved long-term outcomes including a 5-year 
survival of nearly 50%. While allograft function in the ECMO group was worse 
than in transplant recipients not requiring ECMO, the benefits of ECMO in pul-
monary support in the immediate postoperative period is clear [54]. Furthermore, 
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these trends toward better outcomes after primary graft dysfunction appear to 
be improving due to ECMO support; in a large database study of the highest-risk 
transplant patients, patients demonstrate improving outcomes, particularly at 
high-volume centers [55]. In a review of the UNOS database, the use of post-
operative ECMO support for primary graft dysfunction was still associated with 
a 6-month survival of over 60%, and while the subset of ECMO recipients also 
requiring dialysis had a only a 25% 6-month survival, if dialysis was not needed 
survival was over 85% [56].
Unfortunately, while early postoperative ECMO in the setting of primary graft 
dysfunction is associated with reasonable outcomes, the late implementation 
of ECMO postoperatively (after 7 days) does not appear to have the same good 
outcomes. In a 2011 study of late ECMO support in lung transplant patients with 
infection or graft failure, none of the individuals who received late ECMO support 
survived to hospital discharge, due to the propagation of uncontrolled infection or 
organ failure that preempted ECMO support. This suggests that while ECMO can 
provide early support while awaiting graft recovery, it does not represent a means of 
reversing complications existing prior to initiation of ECMO [57].
4.3 Routine ECMO prolongation
With increasing comfort with ECMO as postoperative support, the indications 
for extending its use have continued to expand. In some institutions, for example, 
intraoperative extracorporeal membrane oxygenation has been adopted for all 
unstable lung transplantations. Protocols have been proposed in which ECMO is 
prophylactically extended into the postoperative period based on graft quality and 
the preoperative presence of pulmonary hypertension. A recent single-institution 
analysis of this prophylactic protocol identified patients receiving ECMO as having 
improved survival compared to non-ECMO patients despite higher levels of medical 
complexity. Prophylactic ECMO prolongation is being increasingly recognized as a 
safe option for the routine postoperative support of patients with either marginal 
graft function or underlying pulmonary hypertension [12].
In the same vein, research has been conducted to identify those patients at 
increased risk of ECMO weaning failure after lung transplantation, in order to 
identify those patients who might benefit from continued extracorporeal support. 
Identified risk factors including older donors, longer periods of donor mechani-
cal ventilation, donor PaO2 prior to organ procurement and longer operative 
time [58]. In these patients, prophylactic ECMO support postoperatively may be 
recommended.
4.4 Ex-vivo lung perfusion using ECMO
Ex vivo lung perfusion is another exciting breakthrough for the reconditioning 
of poor quality grafts as high risk of postoperative primary graft dysfunction. In 
this setup, retrieved donor lungs are perfused in an ex vivo circuit. This provides 
an opportunity for transplant surgeons to reassess graft function before trans-
plantation, providing a more accurate window into the likelihood of success in 
transplantation with high-risk donor lungs. The use of an ex vivo circuit allows time 
for toxic waste products and inflammatory cytokines to be filtered out, for more 
optimal recruitment of collapsed lung areas, and for the fluid-overloaded lung 
tissue to be dehydrated by the perfusate high oncotic pressure [59]. In a 2015 study, 
lung transplant recipients who received lungs reconditioned in an ex vivo manner 
demonstrated significantly shorter hospital stay and trends toward shorter length 
of mechanical ventilation [48, 49].
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5. Conclusions
Ultimately, recent advances in ECMO have led it to become a critical tool in the 
armamentarium of the transplant surgeon, in both the preoperative period as a 
bridging strategy, as a tool for cardiopulmonary support during the operation, and 
for the rescue of potentially dysfunctional grafts postoperatively. The use of ECMO 
in lung transplantation has been need-driven in an incredibly complex and medi-
cally challenging complication; innovative thinking by basic scientists and trans-
plant surgeons has led to remarkable improvements in patient outcomes. Continued 
advances in ECMO technologies, deeper experience with the implementation of 
ECMO in complicated clinical situations, and further high-quality research will 
help determine the areas where ECMO can help provide a benefit to lung transplant 
recipients.
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